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age 53 :t~ 8 yrs, LVEF 26 -~- 7, NYHA cL II-IV, stable therapy within two 
weeks) underwent simultaneous 20' recordings at rest of latantonaous lung 
volume (ILV), beat.to.beat arterial oxygen saturation (SAC2, ear probe) and 
heart rata, Analysis of ILV and SaC2 revealed a normal respiratory pattern 
(NR) In 65 p~,tlont~ w h¢l~ 90 h~d u porslstont alteralion ot btoatl~lng will1 
a typical CS In 43 and PB In 47 patients, CS and PB had lower LVEF and 
cardiac Index, and higher wedge proesuro than NR (all p < (},03), During 
n mean foflow-up of 338 • 170 days, 25 cardiac deaths occurred while 10 
patients underwent elective ltoart traneplontatlon, Survival wns significantly 
lower In patient8 with PB and CSR as compared to patients with NR (log 
rank p ~: 0,03) with a RR el 2,9 (95% c,I, ,,, 1,0-8,g) and 4,0 (95% o,L ~, 
t,4-11,7) respectively, However, at mgltlvaffate analysts, nor PB nor CSR 
were Independent prodletors ol doeth after adjustment for NYHA el,, LVEF, 
max VU2 and pulmonary wodga pressure, 
Gonctua/one: In CHF patients, ea roported for nocturnal Chovna.Stokos 
respiration, bro¢~thlng ebnormalltl08 during awake day.time are associated 
with higher Incidence of cardla~ death, HL,wover their prognostic powor 18 not 
Independent of the other known rink lectern and the Increased modallty rate 
Is likely to be related to the moro sovoro homodynamlc Impairment 0! these 
patients, 
~ 6alo©tive AT,1 Blockade With Loaartan Not Does 
Restore Autonomic Balance in I~tlonta With 
Heart Failure 
P,F, b~nklay, E, Nuntl~tn, C,V, Loi~r The Ohio St~f~ Um~mif,,; Cotttml.~,=, 
Ohl(~ US~ 
Anglotent~ln converting nn~ymo Inhlbltom (ACEI'a) hove been shown to re- 
store autonomic balance towards normal in patients with hood failure (HF), 
It Is uncertain whether this effect dorlves Item too Interruption o! angiotonsln 
type I (AT.t) receptor stimulation or extends from oilier propertlos of ACErs, 
Therefore, spectral analysis of head rate variability (HRV) was performed to 
d~rive mad(era of autonem','~ ectlvty u,~Ing 24.hour Holier monitor ecordings 
obtained et bosellno and tollowlng throe munths o! therapy in 35 pat~;. ~ts wtlt~ 
HF enrolled in a medomltod double.blind placebo controlled trial el too so. 
lectlvo AT.1 antagonist Iosartan, The moasum~ of HRV were avomg ~d over 
predetermined qgarttlos o( the 24-hour period (3 AM-9 AM; g AM~ PM; 3 
PM,-9 PM; 9 PM-3 AM) and compared between the placebo (15 patients) and 
Iosaflan (2(} pabents) t~tment gwups, Signifi~ant decreases (p. 0,05) in 
parosympathoticalty mediated high Iroquency HRV were noted in the Iosartan 
treatment group as coml:~red to placebo et all quarttles of day. Sympatheti- 
cally Inlluen¢o~ tow frequency HRV showed no change compared to placebo 
in the quartile between 9AM and 3PM, but at all ether quartiles a significant 
(p ~ 0,(}5) difference was noted with a decrease in the plucebo group and 
no change or a small increase in the Iosartan treatment group. Thomtoro, 
selective AT-1 recepte( blockade with losartan in this group el patients does 
not restore the autonem~c imbalance typtcat of HF towards normal, These 
findings suggest that the previously reported autenomic response to ACEYs 
in HF does not result from diminished AT-t receptor stimulation, 
~8-~ Effect of Oxygen on Sleep, Cognitive Function 
end Sympathetic Activity In Heart Failure With 
Cheyne-StoKea Reeplratlon 
A. Stanfforth, W,J.M. Kinnoar, R. Starling, A,J, Cowley, Univorsi~ Hospital, 
No~hcJham, UK 
Backgruund: Cheyne-Stokos respiration (CSR) is an independent ma~ker el 
mortality in heart failure (HF). Arousal in normal subjects, and CSR in awake 
HF patients is associated with increased sympathetic activity. 
Method: 11 patients with stable heart HF and documented CSR were 
studied in a double blind cross-over study of 24% nectumal O~ vs Air (1 
month each). Sloop quality was assessed by potysomnography, Cognitive 
function was assessed with standard psychometric tests. Symptoms were 
measured using the Epworth Sleepiness Scale, a Quality of Life question- 
naire and Visual Analogue Scales. Neurohormonal activity was measured 
by early morning serum ANP, N-ANP, catecholamines and overnight urinary 
catechelemine xcretion (standardized for urinan/creatinine). 
Baseline Oxygen Air 
Sleep lime (rains) 319 (3B) 290 (36) 265 (44) t
ArousaL°,/hour 9.6 (2.4) t 58 (1 8) 7,5 (1 6) 
Desaruralien/hour 24.1 (4 1 )t 2 81 • .3) 259 (4 5) 1 
Mid SAO2% 84.8 (0.9) t" 90.8 (1.5) 82.6 (2) t 
Apnoea~hour 15.8 (45) 6.1 (2,9) 23.9 (5.2) t
Urine Norepinephrine 89 (3.9) 4.1 (0.6) 8.3 (1 5) I: 
t = p . 0.05 vs baseline. ~" = P. 0.(]5 vs 02 
Results: 90% of apnoeas were central. 02 significantly reduced desatu- 
ration events, apnoeas and arousals. O2 did not improve cognitive function 
or daytime symptoms, 2 patients decompensated on crossing from O~ to 
Air, 02 significantly reduced urlnan/noroptnophrlne excretion, The serum 
neuroondecrlne profile was unaffected by O~. 
Conclusion" 02 Is an effective treatment for CSR in HF, but has no effect 
on symptoms. Ihe pess=billty mat O~ may improve survival in HF with CSR 
requires fudher Investtgtion, 
• Shod-term Homodynaml¢ Effects of BQ-I:13, a 
Selective Endothel ln ETA Receptor Antagonist ,  In 
Palladia With Chronic Head Failure 
P,J, Cowburn, J,J, Morton, J,D, MeAdhur, M.R, MacLean, HJ, Dargio, 
J,J,V, McM,rmy, J,G,F, Cleland, C#nca/Ree~rch Init~tive in Heart F~el.ro, 
Univen~ity of Glasgow and Western I n t i rn~ Glasgow, Scotland, UK 
Endotholln receptor antagonists am thought o have therapeutic potemial in 
chronic heart failure (CHF), The ptdmonary and systemic effects o! selective 
ET^ receptor antagonism have yet to be desclibed in patients with CHF 
We (ntu~,ed BQ.123, a selective ET^ receptor antagonist, into eight CHF 
patients on eonventi0nal medical therapy (200 nmol/min lot 1 hour). ET.I 
(15 pmot,~lin, a close previously shown to cause Wstomic vasoconstlmtion 
in CHF) was co.infused dung the last 15 minutes. HemOdynamcs were 
measured by tharmedllution catheter and artenal ine. Results are expressed 
as mean i standard eviation. 
BQ.123 infusion alone: head r~te was unchanged (73 t 18), mean artenal 
pressure (B6 t tO to 78 ! 13 mmHg, p = 091), light =nat pros.sum (6 t 2 
to 5 ( 2 mmHg, p ~ 0,05), moan pulmooan/ aden/ pressure (23 ~ 11 to 19 
1 9 mmHg, p - 0.g I ), ptdmonan/wedge pressure (14 t 8 to t t t 8 mmHg, 
p - 0,01) and systemic vascular rosistsnco (1480 t 247 to 1287 t 194 
dynes,era/sac', p - 0,01) foil Cardiac index roso (2,38 ~ 0.4610251 t 0.45 
I/minim:', p ,~ (},05), The tall in PVR did not achieve statistics! rag~lk~ance 
{ t 76 t 77 to t 49 ( 41 dynos.cnVsec '~, p = 0.2). ET- 1 co-infusion did not lead 
to systemic vasocoostricbon as obsewed in provious stud0es, 
BQ-123, a soloctive ET^ rocoptor antagonist, led to beneficial shod-term 
homedynamic effects in CHF patients already treated with ACE inhibdo~ 
and diuretics. Prospoctive clinical trials ot ETA selective antagonists in CHF 
am iustilied, 
~___~ Coos Exogenous Melstonln Influence 
Sympathetic Hyperactivity in Heart Failure? A 
Placebo Control led C;Inlcal 1¥181 
F,S. Malik, M.R. Mehra, H.O. Venture. A. AlL F.W. Smart. D.D. Staploton. 
M, PaganL R.V. Milani t, Ochsner &~Ocat Institutions, New Orleans. 
Louisiana, USA: 'Centre Rcerche CaKtovascola,. Mifano, Italy 
Bac'kgmuod: The prognostic significance l sympathetic hyperactp.'tty (SH) in 
determining clinical seventy and mortality in heart failure (HF) remains un(ts- 
putod. We have prevrously demonstrated that nocturnal levels of Melatonin 
(M), a central sympatholytlc hormone from pineal gland, am s=gnilmantly im- 
paired in HF and that exogenous M therapy improves leep patterns in this 
group. We sought o investigate the ability of M replacement to decrease SH 
and restore autonomic balance in HF 
Methods: Sympathetic indices 01 heart rate variability [both lime (RR 
variability) and frequency domain vanables (low frequency spectral power 
(LFP})] were calculated from ECG and the index alpha ot baroreltex sensitivity 
computed from the artenal blood pressure profile at rest, 60 minutes after 
placebo (P) or M (3 mg orally) in a double blind, randOmized, placebo 
controlled crossover study design in HF patients with sinus rhythm (n = 10: 
age 54 ~ 5 yrs, EF = 0.2 ± 0,02: all on ACE inhibitom and Digoxin). 
Results: Compared to placebo, M acutely increased mean RR interval by 
4,7°0 (p = 0.01). The low frequency spectral power percentage decreased 
by 11.3% (p = 0.47); however, the index alpha remained unchanged. 
Placebo Melatontn P 
RR (ms) 937 ,. 218 982 t :200 0.01 
LFP (%) 59.17 52.37 0 4 
Index atpha 21 25 22 45 NS 
Conclusion: Exogenous Melatonin acutely decreases sympathetic hyper- 
activity as assessed by the time domain index el RR variability in HF. Whether 
this short-tern- improvement in sympathetic hyperactivity can be sustained 
long-term remains to be determined. 
